摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-氯-2-甲基-5-硝基吡啶 | 51984-62-4

中文名称
3-氯-2-甲基-5-硝基吡啶
中文别名
——
英文名称
3-chloro-2-methyl-5-nitropyridine
英文别名
——
3-氯-2-甲基-5-硝基吡啶化学式
CAS
51984-62-4
化学式
C6H5ClN2O2
mdl
——
分子量
172.571
InChiKey
KEQYIUZGVFBSNL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    248.7±35.0 °C(Predicted)
  • 密度:
    1.406±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    11
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.17
  • 拓扑面积:
    58.7
  • 氢给体数:
    0
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2933399090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335

SDS

SDS:aeb3aef38bcfd65ee660f38a89a19e73
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] ISOINDOLINONE COMPOUNDS<br/>[FR] COMPOSÉS D'ISO-INDOLINONE
    申请人:MONTE ROSA THERAPEUTICS
    公开号:WO2021069705A1
    公开(公告)日:2021-04-15
    Disclosed herein is a compound or pharmaceutically acceptable salts or stereoisomers thereof of of formula I wherein X1 is linear or branched C1-6 alkyl, C3-6 cycloalkyl, -C1-6 alkyl C3-6 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, C1-6 alkyl C6-10 aryl, C1-6 alkyl 5-10 membered heteroaryl, wherein X1 is unsubstituted or substituted with one or more of halogen, linear or branched C1-6 alkyl, linear or branched C1-6 heteroalkyl, CF3, CHF2, -O-CHF2, -O-(CH2)2-OMe, OCF3, C1-6 alkylamino, -CN, -N(H)C(O)-C1- 6alkyl, -OC(O)-C1-6alkyl, -OC(O)-C1-4alkylamino, -C(O)O-C1-6alkyl, -COOH, - CHO, -C1-6alkylC(O)OH, -C1-6alkylC(O)O-C1-6alkyl, NH2, C1-6 alkoxy or C1-6 alkylhydroxy; X2 is hydrogen, C6-10 aryl, 5-10 membered heteroaryl, -O-(5-10 membered heteroaryl), 4-8 membered heterocycloalkyl, C1-4 alkyl 4-8 membered heterocycloalkyl, -O-(4-8 membered heterocycloalkyl), -O-C1-4 alkyl-(4-8 membered heterocycloalkyl), -OC(O)-C1-4alkyl-4-8 membered heterocycloalkyl or C6 aryloxy, wherein X2 is unsubstituted or substituted with one or more of linear or branched C1-6 alkyl, NH2, NMe2 or 5-6 membered heterocycloalkyl; n is 0, 1 or 2.
    本公开涉及一种化合物或药用可接受盐或其立体异构体,其化学式为I,其中X1为直链或支链的C1-6烷基,C3-6环烷基,-C1-6烷基C3-6环烷基,C6-10芳基,5-10成员杂芳基,C1-6烷基C6-10芳基,C1-6烷基5-10成员杂芳基,其中X1未取代或取代为一个或多个卤素,直链或支链的C1-6烷基,直链或支链的C1-6杂烷基,CF3,CHF2,-O-CHF2,-O-(CH2)2-OMe,OCF3,C1-6烷基氨基,-CN,-N(H)C(O)-C1-6烷基,-OC(O)-C1-6烷基,-OC(O)-C1-4烷基氨基,-C(O)O-C1-6烷基,-COOH,-CHO,-C1-6烷基C(O)OH,-C1-6烷基C(O)O-C1-6烷基,NH2,C1-6烷氧基或C1-6烷基羟基;X2为氢,C6-10芳基,5-10成员杂芳基,-O-(5-10成员杂芳基),4-8成员杂环烷基,C1-4烷基4-8成员杂环烷基,-O-(4-8成员杂环烷基),-O-C1-4烷基-(4-8成员杂环烷基),-OC(O)-C1-4烷基-4-8成员杂环烷基或C6芳氧基,其中X2未取代或取代为一个或多个直链或支链的C1-6烷基,NH2,NMe2或5-6成员杂环烷基;n为0、1或2。
  • [EN] COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY<br/>[FR] COMPOSÉS ET COMPOSITIONS POUR TRAITER DES ÉTATS ASSOCIÉS À UNE ACTIVITÉ DE STING
    申请人:IFM DUE INC
    公开号:WO2021138434A1
    公开(公告)日:2021-07-08
    This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.
    本公开涉及化学实体(例如,一种化合物或药用可接受盐,和/或水合物,和/或共晶体,和/或该化合物的药物组合),可抑制(例如,拮抗)干扰素基因激活器(STING)。所述化学实体可用于治疗条件、疾病或障碍,其中增加(例如,过度)STING激活(例如,STING信号传导)对主体(例如,人类)的病理和/或症状和/或病情进展有贡献(例如,癌症)。本公开还涉及含有相同化学实体的组合物,以及使用和制备这些组合物的方法。
  • PYRIDAZINONE COMPOUND OR ITS SALT, AND HERBICIDE CONTAINING IT
    申请人:ISHIHARA SANGYO KAISHA, LTD.
    公开号:US20200172517A1
    公开(公告)日:2020-06-04
    A novel herbicide having remarkable herbicidal activities against undesired plants is provided. A pyridazinone compound represented by the formula (I) or its salt: wherein X is —O—, —S—, —SO—, —SO 2 — or —N(Y)—; Q is monocyclic aryl which may be substituted by Z, monocyclic heteroaryl which may be substituted by Z or the like; Y is a hydrogen atom or alkyl; Z is halogen, alkyl or the like; R 1 is alkyl, alkenyl or the like; R 2 is a hydrogen atom, alkyl or the like; R 3 is halogen, hydroxy or the like; R 4 is a hydrogen atom, alkyl or the like; and n is an integer of from 0 to 4.
    提供了一种对不受欢迎的植物具有显著除草活性的新型除草剂。一种由以下式(I)或其盐表示的吡啶并酮化合物: 其中X为—O—,—S—,—SO—,—SO2—或—N(Y)—;Q为可以由Z取代的单环芳基,可以由Z取代的单环杂芳基或类似物;Y为氢原子或烷基;Z为卤素,烷基或类似物;R1为烷基,烯烃基或类似物;R2为氢原子,烷基或类似物;R3为卤素,羟基或类似物;R4为氢原子,烷基或类似物;n为0到4的整数。
  • Triazolopyrimidines
    申请人:Gebauer Olaf
    公开号:US20070179295A1
    公开(公告)日:2007-08-02
    The invention relates to novel triazolopyrimidines of formula (I), in which R 1 , R 2 , R 3 , R 4 and X are defined as cited in the description, to a method for producing said substances and to their use for controlling undesirable micro-organisms. The invention also relates to novel intermediate products of the formulae (II), (IV), (V-a) and (V-b), in addition to methods for producing said substances.
    本发明涉及一种新的三唑嘧啶化合物,其化学式为(I),其中R1、R2、R3、R4和X的定义如所述,以及一种制备该化合物的方法及其用于控制不良微生物的用途。本发明还涉及化合物的新中间体,其化学式为(II)、(IV)、(V-a)和(V-b),以及制备该化合物的方法。
  • NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF
    申请人:FUJIWARA Hideyasu
    公开号:US20130116430A1
    公开(公告)日:2013-05-09
    An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. The present invention provides a nicotinamide derivative represented by the following formula (I) (wherein R 1 represents a halogen atom; R 2 represents a C 1-12 alkyl group, a C 2-12 alkenyl group, a C 2-12 alkynyl group, a C 3-8 cycloalkyl group, an aryl group, an ar-C 1-6 alkyl group or a heterocyclic group, each optionally having at least one substituent; R 3 represents an aryl group or a heterocyclic group each optionally having at least one substituent; and R 4 and R 5 each independently represent a hydrogen atom; and R 2 and R 4 may form a cyclic amino group optionally having at least one substituent together with the nitrogen atom to which they bind) or a salt thereof, and a pharmaceutical composition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.
    本发明的目的是提供一种具有优异的Syk抑制活性的化合物和制药组合物。本发明提供了一种由以下式(I)表示的烟酰胺衍生物(其中R1表示卤素原子;R2表示C1-12烷基、C2-12烯基、C2-12炔基、C3-8环烷基、芳基、芳基-C1-6烷基或杂环基,每种均可选地具有至少一个取代基;R3表示芳基或杂环基,每种均可选地具有至少一个取代基;R4和R5各自独立地表示氢原子;且R2和R4可以与它们结合的氮原子一起形成具有至少一个取代基的环状氨基团)或其盐,并且用于治疗Syk相关疾病的制药组合物包括该烟酰胺衍生物或其盐。
查看更多